Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007.
Disease registry
Iran
Survival analysis
Urinary bladder neoplasm
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
12
2019
accepted:
22
09
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
5
1
2021
Statut:
ppublish
Résumé
Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan-Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole. Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50-59, 60-59, 70-79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted.
Sections du résumé
BACKGROUND & OBJECTIVE
OBJECTIVE
Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran.
METHODS
METHODS
Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan-Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole.
RESULTS AND CONCLUSION
CONCLUSIONS
Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50-59, 60-59, 70-79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted.
Identifiants
pubmed: 33391383
doi: 10.30699/ijp.2020.118375.2287
pmc: PMC7691705
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-74Références
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Cancer. 2013 Sep 1;119(17):3219-27
pubmed: 23737352
Transl Androl Urol. 2019 Feb;8(1):5-11
pubmed: 30976562
Am Fam Physician. 2017 Oct 15;96(8):507-514
pubmed: 29094888
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Lancet. 2009 Jul 18;374(9685):239-49
pubmed: 19520422
Eur J Cancer. 2018 May;95:52-58
pubmed: 29635144
Int J Urol. 2017 Oct;24(10):730-734
pubmed: 28543959
Nature. 2017 Nov 8;551(7679):S33
pubmed: 29117156
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Iran J Public Health. 2013;42(2):149-57
pubmed: 23515434
JAMA Oncol. 2015 Dec;1(9):1282-90
pubmed: 26448641
Arch Iran Med. 2008 Sep;11(5):577-80
pubmed: 18759534
Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):681-4
pubmed: 19827894
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Cancer Causes Control. 2018 Nov;29(11):1059-1069
pubmed: 30194549
Curr Addict Rep. 2014 Mar;1(1):53-60
pubmed: 27213132
Sci Rep. 2018 Jan 18;8(1):1129
pubmed: 29348548
Cancer. 1999 Jun 15;85(12):2638-47
pubmed: 10375113
J Urol. 2017 Sep;198(3):552-559
pubmed: 28456635
J Cancer Res Ther. 2018 Apr-Jun;14(3):532-536
pubmed: 29893311
Eur Urol. 2018 Dec;74(6):784-795
pubmed: 30268659
Cancer. 2016 Jul 1;122(13):2012-20
pubmed: 27224661
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Exp Ther Med. 2019 Nov;18(5):3405-3414
pubmed: 31602215
J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053
pubmed: 30181416